ArticleLipids in health and disease2025
Linear association between the composite dietary antioxidant index and the prevalence of sarcopenia in metabolic dysfunction-associated steatotic liver disease.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MASLD and sarcopenia research (2012-2025): a multi-database bibliometric analysis.Frontiers in nutrition · 2026Pooled it
- The Sleep Connection: Exploring the Role of Composite Dietary Antioxidant Index in Sleep Quality Based on NHANES 2007-2014.International journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundA new way to measure the capability of food to inhibit oxidation is the “composite dietary antioxidant index” (CDAI), which helps determine whether sarcopenia progresses because of oxidative stress. Using “National Health and Nutrition Examination Survey” (NHANES) data from 2001 to 2018, this study aimed to explore whether a relationship exists between the CDAI and the development of sarcopenia among individuals who have been confirmed to have “metabolic dysfunction-associated steatotic liver disease” (MASLD).
methodsThe present work functioned as a countrywide representative demographic-based transverse analysis, which included eligible adult MASLD participants from NHANES 2001–2018 and omitted individuals with incomplete data on the CDAI, sarcopenia, and covariates. Multifactorial logistical regression evaluations, constrained cubic spline evaluations, categorized evaluations, and robustness assessments were employed to thoroughly investigate the relationship between the CDAI and sarcopenia in MASLD patients.
resultsThe analysis included a total of 5574 participants who were confirmed to have MASLD. According to the comprehensively adjusted model, the occurrence of sarcopenia among people with MASLD was significantly inversely related to the CDAI (odds ratio 0.946, 95% confidence interval 0.922–0.972, P < 0.0001). In contrast to CDAIs in the lower quartile (Q1), CDAIs in the upper quartile (Q4) were related to a 41.3% reduction in the prevalence of sarcopenia (P for trend < 0.0001). Fewer cases of sarcopenia were linked to increased intake of carotenoid compounds, zinc minerals, selenium minerals, and nutritional vitamins A and E (P for trend < 0.05). A direct dose-dependent correlation was noted for the connection between the CDAI and sarcopenia prevalence, alongside a nonlinear association for the ingestion of vitamins A and E and zinc.
conclusionsAdherence to CDAI-assessed antioxidant dietary patterns may help prevent sarcopenia in the MASLD population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.